Ventas, Inc. (NYSE: VTR) closed at $82.04 on October 9. The stock has returned -2.8% during the last six months, compared to ...
In a phase 3 randomized clinical trial involving 410 people with early Parkinson disease, 52 weeks of nicotinamide riboside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results